Get the Stockscreener App
0.738
0.35%
-0.0026
Skye Bioscience Inc stock is traded at $0.738, with a volume of 209.64K.
It is down -0.35% in the last 24 hours and down -7.69% over the past month.
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
See More
Previous Close:
$0.7406
Open:
$0.74
24h Volume:
209.64K
Relative Volume:
0.57
Market Cap:
$23.66M
Revenue:
-
Net Income/Loss:
$-51.23M
P/E Ratio:
-0.5722
EPS:
-1.2898
Net Cash Flow:
$-41.53M
1W Performance:
-4.28%
1M Performance:
-7.69%
6M Performance:
-81.55%
1Y Performance:
-71.72%
1-Day Range:
$0.7345
$0.7775
1-Week Range:
$0.721
$0.80
52-Week Range:
$0.6844
$5.75
Skye Bioscience Inc Stock (SKYE) Company Profile
Name
Skye Bioscience Inc
Sector
Industry
Phone
(858) 410-0266
Address
11250 EL CAMINO REAL, SUITE 100, SAN DIEGO
Compare SKYE vs PSNYW, SHMD, GOODO, DWLD, QQQE
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SKYE
Skye Bioscience Inc.
|
3.10 | 12.89M | 0 | 0 | 0 | 0.00 |
|
PSNYW
Polestar Automotive Holding Uk
|
4.50 | 350.59M | 2.07B | -1.42B | -1.37B | -0.6765 |
|
SHMD
Schmid Group N V
|
7.26 | 465.95M | 0 | 0 | 0 | 0.00 |
|
GOODO
Gladstone Commercial Corporation
|
20.18 | 372.90M | 0 | 0 | 0 | 0.00 |
|
DWLD
Davis Select Worldwide ETF
|
45.25 | 0 | 0 | 0 | 0 | 0.00 |
|
QQQE
Direxion NASDAQ-100 Equal Weigh
|
103.33 | 0 | 0 | 0 | 0 | 0.00 |
Skye Bioscience Inc Stock (SKYE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-06-25 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Oct-06-25 | Downgrade | Craig Hallum | Buy → Hold |
| Aug-15-25 | Initiated | Evercore ISI | Outperform |
| Feb-28-25 | Initiated | William Blair | Outperform |
| Sep-30-24 | Initiated | Scotiabank | Sector Outperform |
| Sep-10-24 | Initiated | JMP Securities | Mkt Outperform |
| Jul-09-24 | Initiated | Craig Hallum | Buy |
| May-23-24 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-12-24 | Initiated | Oppenheimer | Outperform |
View All
Skye Bioscience Inc Stock (SKYE) Latest News
Skye Bioscience schedules March 2026 earnings release with Q4 and full-year results - Traders Union
Skye Bioscience to Release 2025 Financial Results and Business Update on March 10, 2026 - geneonline.com
Skye Bioscience to Announce 2025 Financial Results and Business Update on March 10, 2026 - GlobeNewswire
Skye Bioscience Stock Quote, Share Price, News and Analysis - Longbridge
SKYE Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Bull Run: Can Skye Bioscience Inc weather a recessionWeekly Stock Recap & Safe Entry Zone Identification - baoquankhu1.vn
SKYE Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
SKYE Earnings History & Surprises | EPS & Revenue Results | SKYE BIOSCIENCE INC (NASDAQ:SKYE) - ChartMill
Skye Bioscience says Kaitlyn Arsenault to step down as CFO effective Feb 20 - marketscreener.com
CFO exits Skye Bioscience (SKYE) with $450k severance; CEO takes accounting duties - Stock Titan
2026-02-19 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Skye Bioscience, Inc. (SKYE) and Encourages Shareholders to Learn More About the Investigation | NDAQ:SKYE | Press Release - Stockhouse
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Skye Bioscience, Inc. (SKYE) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
2026-02-17 | Skye Bioscience, Inc. (SKYE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation | NDAQ:SKYE | Press Release - Stockhouse
Aug Movers: What are the analyst revisions for Skye Bioscience IncIs KNSL stock a good investment in YEARWeekly Trade Report & Low Drawdown Momentum Trade Ideas - baoquankhu1.vn
Bronstein, Gewirtz & Grossman, LLC Encourages Skye Bioscience, Inc. (SKYE) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
2026-02-15 | Bronstein, Gewirtz & Grossman, LLC Encourages Skye Bioscience, Inc. (SKYE) Shareholders to Inquire about Securities Investigation | NDAQ:SKYE | Press Release - Stockhouse
How do insiders feel about Skye Bioscience Inc.Dividend Hike & Weekly Breakout Opportunity Watchlist - mfd.ru
SKYE Should I Buy - Intellectia AI
What’s the outlook for Skye Bioscience Inc.’s sector2025 Trade Ideas & AI Forecasted Entry and Exit Points - mfd.ru
Piper Sandler Maintains SKYE BIOSCIENCE INC(SKYE.US) With Buy Rating, Maintains Target Price $20 - 富途牛牛
SKYE Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Geopolitics Watch: Does Skye Bioscience Inc meet Warren Buffetts criteriaQuarterly Trade Review & Reliable Price Breakout Alerts - baoquankhu1.vn
A | Can Atmos Energy Corporation (AEO) stock retain market dominanceEarnings Overview Summary & Expert Curated Trade Setup Alerts - mfd.ru
2026-02-12 | Bronstein, Gewirtz & Grossman, LLC Is Investigating Skye Bioscience, Inc. (SKYE) And Encourages Shareholders to Connect | NDAQ:SKYE | Press Release - Stockhouse
Aug EndMonth: How does IHS Holding Limited compare to its peersJuly 2025 Institutional & High Accuracy Swing Entry Alerts - baoquankhu1.vn
Can Skye Bioscience Inc. stock reach $100 price targetWeekly Trade Analysis & Technical Confirmation Trade Alerts - mfd.ru
Skye Bioscience (SKYE) director receives grant of 35,000 options - Stock Titan
Skye Bioscience (SKYE) grants CEO 280,000 stock options at $0.82 - Stock Titan
Whats the outlook for Skye Bioscience Incs sectorTrade Analysis Report & Free Fast Gain Swing Trade Alerts - baoquankhu1.vn
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Skye Bioscience, Inc. (SKYE) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Retail Trends: Does Skye Bioscience Inc have a competitive edgeJuly 2025 PreEarnings & Real-Time Volume Analysis Alerts - baoquankhu1.vn
Johnson Fistel, PLLP Begins Investigation on Behalf of - GlobeNewswire
Aug Analyst Calls: Will Skye Bioscience Inc benefit from government policy2025 Valuation Update & Precise Trade Entry Recommendations - baoquankhu1.vn
Movement Recap: Can Skye Bioscience Inc weather a recessionMarket Rally & Long-Term Capital Growth Strategies - baoquankhu1.vn
Here's Why Skye Bioscience (NASDAQ:SKYE) Must Use Its Cash Wisely - Sahm
H.C. Wainwright reiterates Buy rating on Skye Bioscience stock at $20 By Investing.com - Investing.com Nigeria
H.C. Wainwright reiterates Buy rating on Skye Bioscience stock at $20 - Investing.com Australia
William Blair Maintains SKYE BIOSCIENCE INC(SKYE.US) With Buy Rating - 富途牛牛
Skye Bioscience: Nimacimab’s Emerging Clinical Profile and Undervalued Asymmetric Risk/Reward Support Buy Rating - TipRanks
Penny Stock Skye Bioscience Drug Combo With Wegovy Shows Over 22% Weight Loss After One Year - Benzinga
Bronstein, Gewirtz & Grossman, LLC Encourages Skye Bioscience, Inc. (SKYE) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Skye Bioscience (SKYE) Reports Promising Results from CBeyond Ex - GuruFocus
Skye Bioscience announces 52-week data from Phase 2a CBeyond study of nimacimab - TipRanks
Skye reports positive Cbeyond phase 2a extension interim study results for nimacimab - marketscreener.com
Skye Bioscience Reports Interim Results from Phase 2a Study of Nimacimab - TradingView
Skye, Inc. Announces Interim Results from the Combination Cohort of the Company's Phase 2A Extension Study of Nimacimab - marketscreener.com
Obesity drug combo keeps weight off: Skye study shows 22.3% loss - Stock Titan
Chart Watch: Can Skye Bioscience Inc weather a recessionWeekly Trend Summary & Low Risk High Reward Trade Ideas - baoquankhu1.vn
Skye Bioscience accelerates nimacimab clinical trial timeline with early enrollment and extended treatment period - MSN
2026-02-01 | Bronstein, Gewirtz & Grossman, LLC Encourages Skye Bioscience, Inc. (SKYE) Stockholders to Inquire about Securities Investigation | NDAQ:SKYE | Press Release - Stockhouse
Skye Bioscience reports positive results for obesity drug nimacimab By Investing.com - Investing.com South Africa
Skye Bioscience Inc Stock (SKYE) Financials Data
Revenue
Net Income
Cash Flow
EPS
Skye Bioscience Inc Stock (SKYE) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Schwab Andrew J. | Director |
Aug 21 '25 |
Sale |
3.57 |
60,956 |
217,613 |
63,963 |
| 5AM Partners VII, LLC | 10% Owner |
Aug 22 '25 |
Sale |
3.42 |
170,449 |
582,936 |
57,493 |
| 5AM Partners VII, LLC | 10% Owner |
Aug 21 '25 |
Sale |
3.57 |
60,956 |
217,613 |
63,963 |
3.69%
0.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):